Login / Signup

Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.

Rebecca H HabermanKatrina A MacFarlaneSydney CatronJonathan SamuelsRebecca B BlankMichael ToproverZakwan UddinJiyuan HuRochelle CastilloCinty GongKun QianVincent PiguetFrancisco TauskJensen YeungAndrea L NeimannWayne GulliverRalf G ThieleJoseph F MerolaAlexis OgdieProton RahmanSoumya D ChakravartyLihi EderChristopher T RitchlinJose U Scher
Published in: BMJ open (2022)
NCT05004727.
Keyphrases
  • double blind
  • placebo controlled
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • randomized controlled trial
  • phase ii study
  • rheumatoid arthritis
  • open label
  • squamous cell carcinoma
  • cross sectional